SecBot SecBot
SECBOTREPLAY Home › Report › ESPR

ESPR · Esperion Therapeutics completed its acquisition by ArchiMed (via…

Esperion Therapeutics, Inc. · 8-K filed Jul 13, 2026 at 09:10 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jul 13, 2026 at 09:10 ET

Esperion Therapeutics completed its acquisition by ArchiMed (via Essence Parent Inc.) on July 13, 2026, for $3.16 per share in cash plus one contingent value right (CVR) per share, representing up to $100M in aggregate milestone payments. The merger triggers delisting from Nasdaq, a change of control, replacement of the board, and termination of the prior credit agreement with new debt financing from BioPharma Credit.

  • Merger completed on July 13, 2026; each share converted into $3.16 cash plus one CVR
  • Total cash consideration approximately $1.1 billion, funded by equity and debt from BioPharma Credit
  • CVRs entitle holders to up to $100M aggregate contingent payments tied to U.S. net sales milestones for NEXLETOL/NEXLIZET (bempedoic acid) and ENBUMYST (bumetanide)
  • Common stock to be delisted from Nasdaq; Form 15 to be filed to suspend SEC reporting obligations

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access